Overview

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL). To assess that dronedarone is well tolerated in this population.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Amiodarone
Dronedarone